Rilzabrutinib: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Rilzabrutinib. Educational only — not medical advice.

Labeled uses

WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Source: FDA labeling via NIH DailyMed (set 95ffd367…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.